Shares mag. recommending this stock this week. Is this going to be our killer this christmas!!!! any comments anyone?????

Capetown

Could you e me the article? I know you will infringe copywrite if you paste it here.

Cheers

Whoops!

JOHNNY you have mail

capetown

Hi, Thanks for that. I must confess to being a little dubious about rumours even when they appear in the FT but if Glaxo is showing interest ..... who knows?

The sp is starting to look a lot healthier. Lets hope for good news in January

Cheers

i'm a little behind the game on this one, but happy to be back in since exit in late january. a little short profit from idd. out of the frying pan into the fire??!!

Just topped up.

I, although in moments constantly unsure (and more constantly wrong), believe today's slight move up to be a good indicator of CENES. Previous downward movement in the FT100 index has indefinitely meant a downward movement in CENES price (despite changes with CENE's own market value). However today's FT100 dip of 0.7% (46.5pts) was bettered by CENES who went up by 3.28% (0.25pts). Although aware of some the dynamics of market price and some associated ideas, I believe CENES up spike marks a recent and significant anomoly. However DYOR.

have you been drinking jobi?

I was, and I shall be tonight. Seasonal Greetings one and all. & CENES post those results and put me out of my misery.

And to you Jobi. Have a good night.I'm sure CEN will buy you a drink!

Onward & upwards.

Although this time last year the sp headed north & fell back. If we have some good news as expected this month, we should see some exceptional gains this year.

Best wishes to & good luck to one & all for '07.

Added some more yesterday. Hopefully news soon.

CEN could blow any day now.

M6G results probably within 4 weeks imo.

Objective Capital gave CeNeS a Fair Value of 27p last month:

http://www.proactiveinvestors.co.uk/registered/research/objective-cenes-dec06.pdf

Bless them!

CEN said it could receive up to 5 mln usd in milestone payments over the next few years if trials of its experimental smoking cessation drug, being carried out by a licensee, prove successful.

The group out licensed the selective dopamine D1 receptor antagonist, called ADX10061, to Addex Pharmaceuticals in 2002. The group has now started a phase IIa study in the US, and positive results will trigger the payments to CEN.

The company would also receive annual royalties on sales, should ADX10061 reach the market.

'Whilst we are not guaranteed success from any of our carried interests the chance of realising a financial return from Addex is much increased as a result of them commencing this phase II trial,' CEN chief executive Neil Clark said in a statement.

Hi queen1 Your post is indeed good news for the company and the investors

The big news should be out soon.. CeNeS M6G022 Phase III study on treatment with either M6G or Morphine. Effective analgesic could result in lower levels of nausea in patients receiving M6G compared to those receiving morphine. Keep your eyes on this company.

Indeed myway - They've steadied over 8p which they haven't done for a couple of years now so my eyes are firmly fixed on next moves!

This is from the CeNeS site. The results could be announced anytime

Phase III trials of M6G

CeNeS is also pleased to announce that it has successfully completed patient recruitment in its pivotal Phase III trial with M6G in Europe (Study M6G022) for the treatment of post operative pain. The study enrolled over 500 patients at 24 centres in six countries. Results from the study are expected in early 2007.

J

CeNeS 5 February 2007 The Goldman Sachs Group, Inc. ("GS Inc."), had an interest in 38,960,863 ordinary shares of 1p each in the capital of the Company. This interest arose from a beneficial interest held by Goldman Sachs International Limited, a wholly-owned indirect subsidiary of GS Inc. This shareholding represents 8.1 per cent. of the issued share capital of the Company.

They only buy for profit..